Clinical review report Edoxaban (Lixiana) / Canadian Agency for Drugs and Technologies in Health.

Format:

Book

Author/Creator:

Canadian Agency for Drugs and Technologies in Health, author, issuing body.

Language:

English

Subjects (All):

Pulmonary embolism.

Physical Description:

1 online resource (1 PDF file (ix, 88 pages)) : illustrations

Other Title:

Clinical review report Edoxaban

Place of Publication:

Ottawa, Ontario : Canadian Agency for Drugs and Technologies in Health, 2017.

Summary:

Taken orally, Edoxaban is a highly selective, direct, and reversible inhibitor of factor Xa. It has a Health Canada indication for the treatment of venous thromboembolism (VTE) (deep vein thrombosis (DVT) and pulmonary embolism (PE)) and the prevention of recurrent DVT and PE. The manufacturer has requested that edoxaban be reimbursed according to the Health Canada indication. The objective of this report was to perform a systematic review of the beneficial and harmful effects of edoxaban for the treatment of VTE (DVT and PE), and for the prevention of recurrent DVT and PE.

Notes:

Description based on publisher supplied metadata and other sources.